Human epithelial cells may be immortalized with Human papilloma virus E6/E7 and Simian virus sequence oncogenic proteins that block retinoblastoma and P53 gene products. However, the genomic disturbances caused by these oncogenic proteins result in dysfunctional epithelial cells. To overcome this hurdle, a new method to immortalize human epithelial cells has been developed in recent years. Telomere dependent cell aging has been blocked by ectopic expression of the human telomerase reverse transcriptase (hTERT) in these cells. Cells immortalized by hTERT are genetically stable and retain contact inhibition and differentiation potential. These properties make epithelial cells immortalized with this method an ideal experimental model for studies on the biology of human epithelial development. Herein, we summarize this recent technique and provide tips and troubleshooting during transfection and infection studies.
Introduction
Primary human epithelial cell cultures have been used for scientific purposes for many years (1) (2) (3) . However, these cells show rapid senescence and lose their ability to replicate after only a short period in in vitro environments (1, (4) (5) (6) , which restricts the use of primary epithelial cell cultures significantly. In order to overcome this obstacle, primary cells have been immortalized by modifying the cell cycle (1, (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . Immortalized cells can be serially passaged in in vitro serum-free conditions for long periods. In addition, these cells can easily be used for a wide range of clinical and experimental research and in drug development studies. By blocking retinoblastoma and p53 gene products by using the Simian virus 40 (SV40) sequence, Human papilloma virus (HPV)-E6/E7 oncogenes immortalized human epithelial cells (7, 12, (17) (18) (19) (20) . However, it has been shown that these immortalized human epithelial cell lines behave quite differently from primary human epithelial cells as a result of these genomic disturbances (21, 22) . For this reason, a new method to immortalize human epithelial cells has been developed in recent years to improve the activity of the human telomerase reverse transcriptase (hTERT). The introduction of hTERT to human somatic cells leads to the activation of telomerase. In this way, prevention of telomere erosion blocks telomere dependent cell aging. Recently, human esophageal epithelial cells, fibroblasts, retinal pigment epithelial cells, corneal epithelial cells, and meibomian gland epithelial cells have been immortalized using this method and it has been shown that they do not lose their normal human genotypic and phenotypic properties after several passages (23) (24) (25) (26) (27) (28) .
The aim of this review is to summarize this recent technique and provide tips and troubleshooting during transfection and infection studies.
Materials and Methods

Materials required for plasmid hTERT:
• /pRB, immortalize cells through the M1 stage. Several viral oncogenes commonly used are SV40 large T antigen and the E6/E7 proteins of HPV16 virus. Human corneal epithelial cells and sebaceous gland epithelial cells have been immortalized by using the SV40 large T antigen. M2 stage is also called the 'crisis' stage. In contrast to the M1 stage, the M2 stage depends on the shortening of telomeres. Telomeric DNA shortens approximately 50-200 base pairs (bp) after every mitosis in a normal human somatic cell. When the telomere reaches a critical length, the cell enters the M2 stage and apoptosis occurs. Shortening of the telomeres can be prevented by activation of the telomerase reverse transcriptase enzyme. In normal conditions, the telomerase enzyme in somatic cells is silent. The hTERT enzyme includes the necessary catalytic subunit for the activation of the telomerase. Thus, introducing hTERT to human somatic cells prevents telomere-induced cell aging by preventing telomere erosion.
Previous studies have shown that immortalized cells by adenovirus E1A, SV40 large T antigen and viral oncoproteins such as HPV16-E6/E7 are not genomically stable and have different phenotypic characteristics from normal cells. However, cells immortalized by hTERT are genetically stable and have contact inhibition and be capable of differentiation; making this an ideal method.
Obtaining the plasmid with hTERT gene E. coli bacteria containing the pBABE-puro-hTERT plasmid is available at Addgene Inc. (Cambridge, MA, U.S.) (www.addgene.org)
The obtained bacterial stab is cultured in Luria Broth (LB) agar and incubated at 37°C overnight. The following morning, one of the apparent colonies is inoculated to the 500 ml liquid LB medium by touching with a sterile pipette tip. This medium is then incubated at 37°C overnight. The next morning, a bacterial pellet is obtained by centrifuging the medium. The hTERT plasmid DNA obtained from the bacterial pellets can be extracted by using the Maxiprep DNA kit (Qiagen Inc., USA) according to the manufacturers protocol. Note: detailed protocols related to obtaining plasmid can be found at http://www.addgene.org/recipient_in-structions.
Production of retroviruses that containing hTERT plasmid
Human 293GPG cells are transformed human embryonic kidney cells that contain the gene regions of adenoviruses (29) . 293GPG cells are formed by fixed transfection of the GAG and POL genes, which generate vesicular stomatitis virus (VSV)-G protein of vesicular stomatitis virus. These cells are stable packaging cells that contain the GAG, POL and VSV-G protein structure of vesicular stomatitis virus. The surface protein of the virus (VSV-G) was inhibited with a TET repressor (tetracycline in our method) at the packaging cell proliferation stage. Cells are transfected with the desired plasmid DNA when they reach sufficient density and then the cells begn to produce retrovirus in tetracycline-free medium. Transfection efficiencies of 293 cells range from 30% to 60%. Titers can be inducible by wide cDNA inserts (>4 kb).
Retroviral particles can be broken and they have a shorter halflife in less than optimal conditions. Therefore, other procedures and re-suspending the pellets should be done very gently and the materials used should be kept cold to prevent damage to the retroviral particles.
293GPG packaging cells thawed at room temperature (do not centrifuge after thawing) are directly incubated in a 10 cm Petri dish containing 0.3 mg/ml G418 medium with DMEM, 10% fetal bovine serum (inactivated by heat), 1 µg/ml tetracycline and 2 µg/ ml puromycin at 37°C-5% CO 2 until they reach 80% density (Figure 1, 2) (Table 1) . They are then passaged to 15 cm Petri dishes by trypsinizing (1:2 passaging ratio). Passaged cells are ready for transfection when they reach 50% density (Figure 3 ). In the morning of the transfection, cells were transfected, extracted plasmid DNA of hTERT (25 μg) and lipofectamine reagent (156 μl) (Invitrogen Inc., Carlsbad, USA) are mixed separately with 1.8 ml OptiMEM (Gibco Life Technologies Inc., Carlsbad, USA). Then, they are gently mixed together at room temperature and suspended to form a complex with DNA and lipofectamine for 45 minutes. This mixture is added dropwise onto the 293GPG packaging cells and the cells are incubated at 37°C for 10 hours. Then, 12 ml of virus-producing medium (tetracycline, puromycin and G418-free; containing DMEM, 10% FBS, 50 U/ml penicillin-streptomycin) is added to the cells which are incubated at 37°C overnight ( Table 2 ). The day following transfection is defined as day 0, and the virus-containing cell culture supernatants are collected on days 2, 3, 4, 5, and 6 and deposited in a sterile vial at 4°C. Then, the virus pellets are obtained serially by precipitation at 25.000g at 4°C.These pellets are dissolved in TNE buffer (50mM Tris pH 7.8, 130 mMNaCl, 1 mM EDTA) and kept at 4°C for one day and are preserved by freezing at -80°C until the day of use. (Note: Foam should not be produced in any of these stages). 
Infection of epithelial cells by the produced virus
